Clinical Data Novo Nordisk microRNA drug fluffs its lines in heart failure PharmaphorumA microRNA-targeting drug acquired by Novo Nordisk when it bought Cardior in a $1bn-plus deal has generated disappointing results in heart failure.CardiovascularRead full story pharminent May 11, 2026 (Last updated: May 16, 2026) Pharmaphorum A microRNA-targeting drug acquired by Novo Nordisk when it bought Cardior in a $1bn-plus deal has generated disappointing results in heart failure. Cardiovascular Read full story Post navigation Previous: Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucherNext: Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026